These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33498915)

  • 21. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
    Berchialla P; Zohar S; Baldi I
    Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research methods to change clinical practice for patients with rare cancers.
    Billingham L; Malottki K; Steven N
    Lancet Oncol; 2016 Feb; 17(2):e70-e80. PubMed ID: 26868356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
    Tidwell RSS; Peng SA; Chen M; Liu DD; Yuan Y; Lee JJ
    Clin Trials; 2019 Dec; 16(6):645-656. PubMed ID: 31450957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early.
    Huang B; Giannini EH; Lovell DJ; Ding L; Liu Y; Hashkes PJ
    Contemp Clin Trials; 2014 Jul; 38(2):204-12. PubMed ID: 24833067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting.
    Jazić I; Liu X; Laird G
    J Biopharm Stat; 2021 Jul; 31(4):507-522. PubMed ID: 34053399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Random-effects meta-analysis for systematic reviews of phase I clinical trials: Rare events and missing data.
    Kim MO; Wang X; Liu C; Dorris K; Fouladi M; Song S
    Res Synth Methods; 2017 Jun; 8(2):124-135. PubMed ID: 27285532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian Statistics for Medical Devices: Progress Since 2010.
    Campbell G; Irony T; Pennello G; Thompson L
    Ther Innov Regul Sci; 2023 May; 57(3):453-463. PubMed ID: 36869194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian methods for the design and analysis of noninferiority trials.
    Gamalo-Siebers M; Gao A; Lakshminarayanan M; Liu G; Natanegara F; Railkar R; Schmidli H; Song G
    J Biopharm Stat; 2016; 26(5):823-41. PubMed ID: 26247350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.
    Hampson LV; Whitehead J; Eleftheriou D; Tudur-Smith C; Jones R; Jayne D; Hickey H; Beresford MW; Bracaglia C; Caldas A; Cimaz R; Dehoorne J; Dolezalova P; Friswell M; Jelusic M; Marks SD; Martin N; McMahon AM; Peitz J; van Royen-Kerkhof A; Soylemezoglu O; Brogan PA
    PLoS One; 2015; 10(3):e0120981. PubMed ID: 25822991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.
    Ramanan AV; Hampson LV; Lythgoe H; Jones AP; Hardwick B; Hind H; Jacobs B; Vasileiou D; Wadsworth I; Ambrose N; Davidson J; Ferguson PJ; Herlin T; Kavirayani A; Killeen OG; Compeyrot-Lacassagne S; Laxer RM; Roderick M; Swart JF; Hedrich CM; Beresford MW
    PLoS One; 2019; 14(6):e0215739. PubMed ID: 31166977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial.
    Park Y; Fullerton HJ; Elm JJ
    Contemp Clin Trials; 2019 Nov; 86():105852. PubMed ID: 31614215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian methods in health technology assessment: a review.
    Spiegelhalter DJ; Myles JP; Jones DR; Abrams KR
    Health Technol Assess; 2000; 4(38):1-130. PubMed ID: 11134920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules.
    Zohar S; Latouche A; Taconnet M; Chevret S
    Comput Methods Programs Biomed; 2003 Oct; 72(2):117-25. PubMed ID: 12941516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian adaptive clinical trials: a dream for statisticians only?
    Chevret S
    Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian methods to compare dose levels with placebo in a small n, sequential, multiple assignment, randomized trial.
    Fang F; Hochstedler KA; Tamura RN; Braun TM; Kidwell KM
    Stat Med; 2021 Feb; 40(4):963-977. PubMed ID: 33216360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of the impact of rare disease characteristics on research methodology.
    Whicher D; Philbin S; Aronson N
    Orphanet J Rare Dis; 2018 Jan; 13(1):14. PubMed ID: 29351763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.